Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease

29Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer’s disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer’s disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ-positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer’s disease.

Cite

CITATION STYLE

APA

Hansson, O., Cullen, N., Zetterberg, H., Blennow, K., & Mattsson-Carlgren, N. (2021). Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease. Annals of Clinical and Translational Neurology, 8(1), 259–265. https://doi.org/10.1002/acn3.51253

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free